title: FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court Hurdles.
abstract: As first biosimilar approval nears, key questions remain.
authors: Stephen
authors: S
authors: Barlas